Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aclidinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 17/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 16/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | TACR1 | P25103 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclidinium SCHEMBL72141 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL2075481 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72693 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL29351588 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Aclidinium SCHEMBL72694 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73281 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73282 | 0.98 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL71791 | 0.95 | CHRM3 (0.91) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73023 | 0.95 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73022 | 0.95 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | claimed |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL, S.A. (ES) | 2018-07-19 | — | — | US | claimed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | claimed |
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | claimed |
| US-RE46417-E1 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | ALMIRALL, S.A. (ES) | 2017-05-30 | — | — | US | claimed |
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2017-02-23 | — | — | US | claimed |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2016-10-13 | — | — | US | claimed |
| WO-2016162878-A1 | AN ADVANTAGEOUS PROCESS FOR PREPARING 1-AZONIABICYCLO[2.2.2]OCTANE,3-[(HYDROXYDI-2-THIENYLACETYL)OXY]-1-(3¬PHENOXYPROPYL)-, BROMIDE, (3R)- AND ITS NOVEL CRYSTALLINE FORM-I | HARMAN FINOCHEM LIMITED (IN) | 2016-10-13 | — | — | WO | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | GRAS ESCARDO JORDI | 2005-12-29 | — | — | US | claimed |
| WO-2005115462-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115467-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115466-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | claimed |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | ESCARDO JORDI G | 2005-12-01 | — | — | US | claimed |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | GRAS ESCARDO JORDI | 2005-12-01 | — | — | US | claimed |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-07-08 | — | — | US | claimed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | claimed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | claimed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CHRM3 2/4885CHRM2 8/4885CHRM1 4/4885 |
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ADRB2, ADRB3, CHRM3 | CHRM3 3/4885CHRM2 4/4885CHRM1 11/4885 |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | CHRM3 1/4885CHRM2 4/4885CHRM1 8/4885 |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | CHRM3 3/4885CHRM2 4/4885CHRM1 11/4885 |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO2, CHRM3 | CHRM3 3/4885CHRM2 11/4885CHRM1 8/4885 |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | CHRM3, CBR1, CHRNB1 | CHRM3 1/4885CHRM2 5/4885CHRM1 10/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | CHRM3 2/4885CHRM2 8/4885CHRM1 11/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CHRM3 2/4885CHRM2 10/4885CHRM1 7/4885 |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.